Interleukin-2 - the drug with many uses.
..."Maxim Pharmaceuticals (AMEX:MMP, SSE:MAXM) announced today the first clinical data demonstrating that combination treatment with Maxamine(TM)(histamine) and interleukin-2 (IL-2) increased a key indicator of white blood cell function in patients with acute myelogenous leukemia (AML)."...
..."AML patients treated with Maxamine and IL-2 to date," said Mats Brune, M.D., Ph.D., Department of Hematology, Sahlgrenska University Hospital, Gothenburg, Sweden, a co-author"...
..."combination of Maxamine and low doses of IL-2 to prevent relapse and prolong leukemia-free survival, while maintaining a good quality of life for the patients during treatment," said Dr. Kurt Gehlsen, Maxim's Chief Technical Officer. Based on the results of the Phase II studies, the Company initiated a 360-patient Phase III trial of Maxamine Therapy in the treatment of AML patients that is currently underway in 12 countries, with clinical sites based in the U.S., Europe, Canada, Australia and Israel"...
..."With many forms of cancer, the capacity of the patient's immune system to detect and destroy foreign cells is compromised. The rationale behind the combination therapy with Maxamine and cytokines such as IL-2 or interferon-alpha is to stimulate and protect NK cells and T cells, both of which are white blood cells with protective effects against leukemic cells"...
..."In the AML patients with reduced CD3 zeta, the CD3 zeta expression was rapidly and significantly up-regulated in greater than 80% of courses of treatment with Maxamine and IL-2. This up-regulation of CD3 zeta expression was observed in NK cells as well as in T cells, including CD4 cells ("memory cells") and CD8 cells ("cytotoxic cells")"...
newsalert.com |
